The stock price performance over the year has been a mixed bag, resulting in a range of outlooks from optimistic to pessimistic depending on the observer. The index has shown a price gain of 46.34% this year. Over the last six months, there has been a weaker performance of 147.40%. The price of VRNA fallen by 24.31% during the last 30 days period. For the last 5-days stocks have improved 10.20%.
Verona Pharma Plc ADR’s stock has seen a smooth market performance. The company’s stock achieved a 1-year high of $65.50 on 02/21/25, and the lowest price during that time was $11.39, recorded on 05/30/24.
52-week price history of VRNA Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Verona Pharma Plc ADR’s current trading price is 3.76% away from its 52-week high, while its distance from the 52-week low is 496.66%. The stock’s price range over this timeframe has been between $11.39 and $65.50. The shares of the Healthcare sector company recorded a trading volume of approximately 2.08 million for the day, which was comparatively higher than the average daily volume of 1.22 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Verona Pharma Plc ADR (VRNA) has experienced a quarterly rise of 94.50% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 5.56B and boasts a workforce of 79 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 43.54, with a change in price of +40.32. Similarly, Verona Pharma Plc ADR recorded 1,169,100 in trading volume during the last 100 days, posting a change of +145.88%.
VRNA’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for VRNA stands at 1.72. Similarly, the long-term debt-to-equity ratio is also 1.71.
VRNA Stock Stochastic Average
The raw stochastic average for Verona Pharma Plc ADR over the last 50 days is presently at 97.72%. This reflects a surge from the raw stochastic average of the previous 20 days, which was noted at 95.74%. Further, the company’s Stochastic %K and %D values for the last 20 days were 91.24% and 90.49%, respectively.
